melphalan + methotrexate

Melphalan + methotrexate is a combination of two small molecule chemotherapeutic agents. Melphalan is an alkylating agent of the nitrogen mustard type, primarily used in the treatment of multiple myeloma and ovarian carcinoma, as well as for high-dose conditioning prior to hematopoietic stem cell transplantation. Methotrexate is an antimetabolite and antifolate drug that inhibits dihydrofolate reductase, interfering with DNA synthesis and cell replication. The combination may be used in oncology settings where multi-agent chemotherapy regimens are indicated, though this specific pairing does not have a unique brand or code name and is not widely established as a fixed combination product[1][2][4]. Both drugs act through distinct mechanisms to inhibit cancer cell proliferation.